FORM 10-QSB

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                   Quarterly Report Under Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                 For the Quarterly Period Ended October 31, 2004
                        Commission File Number: 000-49972

                        IN VIVO MEDICAL DIAGNOSTICS, INC.
           ----------------------------------------------------------
             (Exact name of registrant as specified in its charter)

              Colorado                                         84-1579760
    -------------------------------                       -------------------
    (State or other jurisdiction of                        (I.R.S. Employer
      incorporation or organization)                      Identification No.)


     The Green House, Beechwood Business Park North,
                   Inverness, Scotland                         IV2 3BL
     -------------------------------------------------        ----------
        (Address of principal executive offices)              (Zip Code)

                 Issuer's telephone number: 011 44-1463-667-347
                                            -------------------

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding  twelve months (or for such shorter period that the registrant was
required  to file  such  reports);  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.               YES [X]         NO [ ]

Indicate  by check mark  whether  the  registrant  is an  accelerated  Filer (as
defined in Rule 12-b-2 of the Exchange Act).     YES [ ]         NO [X]
Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the close of the latest practical date.

          Title of Class                          Number of Shares Outstanding
          --------------                          ----------------------------
Common Stock (par value $0.001 per share)      51,376,686 as of January 31, 2005

<PAGE>

                        IN VIVO MEDICAL DIAGNOSTICS, INC.


                                      INDEX



                                                                         Page
                                                                         Number
                                                                         ------

 PART I. FINANCIAL INFORMATION
 Item 1. Financial Statements

 Consolidated Balance Sheets
 October 31, 2004 (Unaudited) and July 31, 2004.........................   1
 Consolidated Statements of Operations
 Three Months Ended October 31, 2004 and October 31, 2003 (Unaudited)
 and Inception (March 26, 1997)through October 31, 2004 (Unaudited).....   2
 Consolidated Statements of Cash Flows
 Three Months Ended October 31, 2004 and October 31, 2003 (Unaudited)
 and Inception (March 26, 1997) through October 31, 2004 (Unaudited)....   3
 Notes to the Consolidated Financial
 Statements (Unaudited).................................................   4
 Item 2. Management's Discussion and Analysis of
 Financial Condition and Plan of Operations............................    8
 Item 3. Controls and procedures.......................................    8


 PART II. OTHER INFORMATION
 Item 1. Legal Proceedings ............................................   12
 Item 2. Changes in Securities.........................................   12
 Item 3. Defaults Upon Senior Securities...............................   12


 Item 4. Submission of Matters to a Vote of Security
         Security Holders..............................................   12


 Item 5. Other Information ............................................   12


 Item 6. Exhibits and Reports on Form 8-K..............................   12

 Signatures............................................................   13

<PAGE>

<TABLE>
               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS
<CAPTION>

                                                                      October 31,     July 31,
                                                                         2004           2004
                                                                      -----------    -----------
                                                                      (unaudited)
<S>                                                                   <C>            <C>
                                     ASSETS
     CURRENT ASSETS:

Cash and cash equivalents .........................................   $    48,423    $    46,191
Accounts receivable ...............................................       209,710        250,444
Prepaid expenses ..................................................        25,137         23,576
                                                                      -----------    -----------



 TOTAL CURRENT ASSETS .............................................       283,270        320,211
                                                                      -----------    -----------

Property, plant & Equipment, net ..................................        42,127         42,781


Other assets ......................................................         6,000          6,000

                                                                      -----------    -----------
TOTAL ASSETS ......................................................   $   331,397    $   368,992
                                                                      ===========    ===========

                      LIABILITIES AND SHAREHOLDERS' DEFICIT

CURRENT LIABILITIES:

Accounts payable ..................................................   $   608,154    $   431,402
Accrued liabilities ...............................................       164,050        168,258
Indebtedness to related parties ...................................     1,898,937      2,021,782
                                                                      -----------    -----------
TOTAL CURRENT LIABILITIES .........................................   $ 2,671,141    $ 2,621,442
                                                                      -----------    -----------
Commitments and contingencies

SHAREHOLDERS' DEFICIT:

4% Convertible Preferred stock, $0.001 par value; 50,000,000 shares
authorized; 34,343,662 issued and outstanding .....................        34,344         34,344
Common stock, $0.001 par value; 100,000,000 shares authorized;
51,376,686 and 50,822,686 issued and outstanding ..................        51,376         50,822
Additional paid-in capital ........................................     1,102,992      1,013,786
Accumulated other comprehensive loss ..............................      (684,169)      (644,135)
Deficit accumulated during the development stage ..................    (2,844,287)    (2,707,267)
                                                                      -----------    -----------
Total shareholder's deficit .......................................    (2,339,744)    (2,252,450)
                                                                      -----------    -----------

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT .......................   $   331,397    $   368,992
                                                                      ===========    ===========
</TABLE>
           See accompanying notes to consolidated financial statements

                                       -1-
<PAGE>

<TABLE>
               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)
<CAPTION>


                                          THREE MONTHS ENDED            Inception
                                              OCTOBER 31,            (March 26, 1997)
                                      ----------------------------       through
                                          2004            2003       October 31, 2004
                                      ------------    ------------    ------------
<S>                                   <C>             <C>             <C>
Revenues ..........................   $    417,405    $    142,902    $  1,838,235

Cost of Revenues ..................            260             736         237,777
                                      ------------    ------------    ------------
Gross Profit ......................        417,145         142,166       1,600,458

Other Operating Income ............           --            42,000          --
                                      ------------    ------------    ------------
                                           417,145         184,166       1,600,458

Research and development expenses .         98,657          84,741       1,531,421
General and administrative expenses        455,508         318,836       5,343,658
                                      ------------    ------------    ------------

                                           554,165         403,577       6,875,079
                                      ------------    ------------    ------------

Operating loss ....................       (137,020)       (219,411)      5,274,621

                                      ------------    ------------    ------------

Gain from extinguishment of debt ..           --              --         2,430,334

Loss before taxes .................       (137,020)       (219,411)     (2,844,287)

Income taxes ......................           --              --              --
                                      ------------    ------------    ------------

Net loss ..........................   $   (137,020)   $   (219,411)   $ (2,844,287)
                                      ============    ============    ============


Basic and diluted loss per share ..    $     (0.00)    $     (0.00)
                                       ============    ============

Weighted average number of shares .     85,443,349      10,912,080
                                       ============    ============
</TABLE>

          See accompanying notes to consolidated financial statements.

                                       -2-
<PAGE>

<TABLE>
               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                        -
                                   (Unaudited)
<CAPTION>

                                                    THREE MONTHS ENDED         Inception
                                                        OCTOBER 31,         (March 26, 1997)
                                                 -------------------------       through
                                                    2004            2003     October 31, 2004
                                                 -----------   -----------   -------------
<S>                                              <C>               <C>         <C>
CASH FLOWS FROM OPERATING ACTIVITIES
   Net loss..................................... $ (137,020)   $  (219,411)  $   2,844,287
   Adjustments to reconcile net loss to net
   cash used by operating activities:
     Depreciation and amortization..............      4,069          4,956         111,239
     Legal fees paid with common stock..........     90,000           -             90,000
     Changes in assets and liabilities:
       Accounts receivable......................     43,746        (15,800)        (93,736)
       Prepaid expenses.........................     (1,277)          -            (24,853)
       Accounts payable.........................    171,565        226,926         450,712
       Accrued liabilities......................     (6,230)          -            145,238
       Other....................................    (64,070)          -             67,174
                                                 -----------   -----------   -------------
NET CASH PROVIDED (USED BY) OPERATING ACTIVITIES    101,335        (3,329)     (2,097,,961)
                                                 -----------   -----------   -------------
CASH FLOWS FROM INVESTING ACTIVITIES

    Purchase of property and equipment, net.....     (2,900)           -          (137,466)

                                                 -----------   -----------   -------------
NET CASH USED BY INVESTING ACTIVITIES...........     (2,900)           -          (137,466)
                                                 -----------   -----------   -------------

CASH FLOWS FROM FINANCING ACTIVITIES
     Repayment to affiliates, net...............    (96,203)           -         1,911,552
     Advances from related parties..............       -               -             5,641
     Proceeds from sale of common stock.........       -               -            31,776
     Proceeds from issuance of preferred stock..       -               -           326,155
                                                 -----------   -----------   -------------
NET CASH USED BY FINANCING ACTIVITIES...........    (96,203)           -         2,275,124
                                                 -----------   -----------   -------------
Net increase (decrease) in cash.................      2,232          (3,329)        48,423
Cash and cash equivalents, beginning............     46,191           9,507           -
                                                 -----------   -----------   -------------
Cash and cash equivalents, ending...............  $  48,423      $    6,178      $  48,423
                                                 ===========   ===========   =============
</TABLE>

             See accompanying notes to consolidated financial statements.

                                       -3-
<PAGE>


               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)

NOTE 1 - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES


In Vivo Medical  Diagnostics,  Inc.,  ("the  Registrant",  "the  Company" or "In
Vivo") was formerly known as Sports  Information  and Publishing  Corp.,  and is
engaged in the development of exciting lateral applications of novel measurement
techniques in medical devices with near patient testing applications.

On July 30,  2004,  the Company  acquired  100% of the capital  stock of In Vivo
Medical Diagnostics Inc., a Delaware Corporation (In Vivo DE) and formerly known
as Hall Effect Medical Products Inc., in exchange for an aggregate of 34,343,662
shares  of our 4%  voting,  redeemable,  convertible  preferred  stock  (the "4%
Preferred  Stock")  and  38,636,453  shares  of our  common  stock  (the  "Share
Exchange").  As  a  result  of  the  share  exchange,  In  Vivo  DE  became  our
wholly-owned  subsidiary and changed its name from Hall Effect Medical Products,
Inc. to its current name, In Vivo Medical  Diagnostics  Inc. and our fiscal year
end was changed  from  September  30 to July 31  effective  with the fiscal year
ended July 31, 2004.

In connection with the Share Exchange, the Company:

     o    issued  to the  former  holders  of  8,000,000  shares  of In  Vivo DE
          preferred stock, an aggregate of 34,343,662 shares of our 4% Preferred
          Stock;

     o    issued to the former holders of shares of In Vivo DE common stock,  an
          aggregate of 38,636,453 shares of our common stock;

     o    issued 1,636,233  additional  shares of our common stock to holders of
          $467,495  of  promissory  notes  issued by In Vivo DE's  wholly  owned
          subsidiaries Hall Effect Technologies Ltd. and Jopejo Ltd. in exchange
          for the  cancellation  of such  notes;  which  notes  were  originally
          convertible into 750,000 shares of In Vivo DE common stock; and

     o    agreed to cause the resignation of all current members of our board of
          directors   and  appoint  new   directors  as  designated  by  certain
          shareholders or affiliates of In Vivo.

Each full  share of our 4%  Preferred  Stock is  convertible  at any time  after
October 31, 2005, at the option of the holder, into one full share of our common
stock.  The shares of 4% Preferred  Stock vote,  together  with our  outstanding
common stock on an "as converted"  basis,  at any regular or special  meeting of
our stockholders  called for the purpose of electing directors of our company or
to vote on any  other  matter  requiring  shareholder  approval  under  Colorado
corporate law.  Assuming  conversion of all of our shares of 4% Preferred Stock,
the  76,200,000  shares  of common  stock  issued  and  issuable  to the  former
securityholders of In Vivo DE and its subsidiaries represent  approximately 88 %
of our fully diluted common stock.


We have two wholly owned  subsidiaries,  IVMD(UK) Ltd.  ("IVMD") and Jopejo Ltd.
("Jopejo"),  both of which are incorporated  under the laws of England and Wales
and based in Inverness, Scotland.

IVMD was formed in August 2004 from Hall Effect Technologies Ltd ("HET") who had
built  a  platform  of  patents   from  which  to  exploit   unique   commercial
applications.   HET's  operations  were,  historically,   funded  in  part  from
development contracts and government grants, with a majority of funding provided
by its previous major shareholder,  Abacus.  The controlling  interest of Jopejo
Ltd, a biotech research company utilizing similar  development  techniques,  was
purchased  by Abacus  and the  operations  of the  companies  merged to  achieve
development savings.

                                       -4-
<PAGE>

               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


BUSINESS

INTRODUCTION.

HET and  Jopejo  are  developing  a group of  medical  diagnostic  products  for
personal and  professional  use.  These  products are based on  technology  that
utilizes the "Hall Effect"  phenomenon  discovered over 100 years ago, for which
In Vivo scientists are currently  developing practical  applications.  HET is in
the final  development  stages of  groundbreaking  medical devices for measuring
levels of blood  coagulation  and  other  applications  for the  cardio-vascular
market.  Other medical applications being addressed by HET's patented technology
include the  measuring of blood sugar  levels for the diabetes  market and other
conditions  where  measuring  and imaging is  essential.  HET has a  substantial
patent portfolio relating to its technology. In addition, Jopejo has developed a
patented  pregnancy  monitoring  technology,  and is also in the late  stages of
developing new and better monitoring  devices that utilize signal processing for
the late-term pregnancy market.

HET was formed in January  2001 with the goal of building a platform of patented
technologies  from  which  to  exploit  unique  commercial  applications.  HET's
operations have,  historically,  been funded in part from development  contracts
and, in majority,  by its previous major  shareholder,  Westek Employee Benefits
Trust  ("Abacus").  The  controlling  interest  of Jopejo,  a bio-tech  research
company utilizing similar development processes, was purchased by Abacus and the
operations of the two companies  were merged to exploit the combined  technology
base.

The  fundamental  premise is in the  transfer  of  measurement  technology,  the
principles of which are known and established in the world of physical  science,
into medical devices with global near-patient applications. This is done through
the creation of novel,  patented methods and apparatus for which HET is the sole
owner of the intellectual property.

Basis of Presentation

The  unaudited  financial  statements  included  in the Form  10-QSB  have  been
prepared in accordance with generally accepted accounting principles for interim
financial  information and with the  instructions to Form 10-QSB and Item 310(b)
of  Regulation  SB of the  Securities  and Exchange Act of 1934.  The  financial
information furnished herein reflects all adjustments,  which, in the opinion of
management,  are necessary for a fair  presentation  of the Company's  financial
position, the results of operations and cash flows for the periods presented.

                                       -5-
<PAGE>

               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)

Certain  information and footnote  disclosures  normally  contained in financial
statements prepared in accordance with generally accepted accounting  principles
have been omitted, pursuant to such rules and regulations.

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
the reported amounts of revenues and expenses during the reported period. Actual
results could differ from those estimates.

GOING CONCERN

     The Company had a working  capital  deficiency of $ for the fiscal year (10
months)  ended July 31, 2004 and $ for the three months ended  October 31, 2004.
At October 31, 2004, the Company had an accumulated  deficit of $1,194,083,  and
had  incurred a loss of $113,835  for the three  months then ended and a loss of
$282,700 for the year ended July 31, 2004. In addition,  the Company's available
cash of $ at October 31, 2004 is not sufficient to fund  operations for the next
twelve months.  Although the Company is in the development stage, such recurring
losses and working capital deficiency raise doubt about the Company's ability to
continue as a going concern.  The Company's financial  statements do not include
any adjustments  relating to the recoverability and reclassification of recorded
asset  amounts or to  amounts  and  classification  of  liabilities  that may be
necessary should the Company be unable to continue as a going concern.

NOTE 2 - INFORMATION ON THE OPERATING SUBSIDIARIES AND BUSINESS PLAN


NOTE 3 - Earnings per share -

      The  average  number of shares  outstanding  for the period  includes  the
34,343,662  issued shares of the Company's  Preferred  convertible stock as such
shares have equivalent voting rights to those of common shareholders.


NOTE 4 - SUBSEQUENT EVENTS

     On December 22, 2004,  the Company  entered into a  Subscription  Agreement
with an accredited investor,  NITE Capital,  L.P. (the "Investor"),  pursuant to
which the Investor purchased an aggregate  principal amount of $250,000 in an 8%
promissory  note,  and 60,096  shares of our common  stock,  par value $.001 per
share. The aforementioned  securities were issued to the Investor by us pursuant
to Section 4(2) of the Securities Act of 1933, as amended.

     The  promissory  note bears simple  interest at 8% per annum payable on the
maturity  date,  which is the  earlier  of (i)  June  22,  2005 of (ii) the date
subsequent  to the  date of the  note  which we  enter  into  any  financing  or
financings  of any type  aggregating  $1,500,000 or more. If we do not repay the
note within 3 business  days of the  maturity  date  (either on June 22, 2005 of
upon subsequent financing as described in the preceding sentence),  the Investor
may, at its sole  option,  convert such note into common stock at a 50% discount
of the average of the three  lowest  closing  prices for our common stock on the
NASD OTC Bulletin  Board (or such other  principal  market or exchange where our
common  stock is listed or  traded at the time of  conversion)  for the ten days
immediately preceding the maturity date.

                                       -6-
<PAGE>

               IN VIVO MEDICAL DIAGNOSTICS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


     We may prepay the principal amount of the note, in whole or in part without
premium or  penalty,  at any time.  In the event that we intend to prepay any or
all of the  outstanding  principal  or  interest  on the note,  we must  provide
written notice to the Investor at least 10 days prior to the proposed prepayment
date. In the event that we,  subsequent to the date of the note,  enter into any
financing or financings  of any type  aggregating  $1,000,000,  then and in such
event we shall be  required  to make a partial  prepayment  of  $175,000  of the
principal  amount of the note and the pro rata share of interest accrued to date
on such portion of the note.  In addition,  in the event that we,  subsequent to
the  date of the  note,  enter  into any  financing  or  financings  of any type
aggregating  more than  $1,000,000  but less than  $1,500,000,  then and in such
event the amount of the  partial  prepayment  shall be  increased  on a pro-rata
basis (up to the full  principal  amount  of the note and the pro rata  share of
interest  accrued  to date on the note in the case of a  financing  totaling  at
least  $1,500,000).  We are  required  to notify the  Investor in writing of any
financing  which results in In Vivo being  required to prepay the note, in whole
or in part,  prior to June 22,  2005,  and to make  such  payment  within  three
business days after we receive the proceeds of such financing.

     In  addition,  we entered into a  Registration  Rights  Agreement  with the
Investor dated as of December 22, 2004. If we at any time after the date hereof,
but before  December 22, 2005,  propose to register any of our securities  under
the  Securities  Act of 1933, as amended  (other than pursuant to a registration
statement  in  connection  with an  acquisition  or in a manner  which would not
permit the registration of the shares issuable  pursuant to the note for sale to
the public,  such as on Form S-8 or on Form S-4 or other  comparable  form),  we
shall  include the shares  issuable  pursuant to the note in such  registration.
Provided,  however, that if, at any time after giving such written notice of our
intention  to  register  any of  the  Investor's  securities  and  prior  to the
effective  date of the  registration  statement  filed in  connection  with such
registration,  we may  determine  for any reason not to register or to delay the
registration.  We must give written notice of such determination to the Investor
and thereupon  shall be relieved of our  obligation  to register any  securities
issued  or  issuable  in  connection  with such  registration  (but not from our
obligation to pay registration  expenses in connection  therewith or to register
the securities in a subsequent registration).

                                       -7-
<PAGE>


ITEM 2.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF RESULTS OF  OPERATIONS  AND
         LIQUIDITY AND CAPITAL RESOURCES

     GENERAL

     The following  discussion and analysis  should be read in conjunction  with
the Consolidated  Financial  Statements and Notes thereto appearing elsewhere in
this Form 10-Q.

     This  management's  discussion  and  analysis of financial  conditions  and
results of operations contains certain  "forward-looking  statements" as defined
in the  Private  Securities  Litigation  Reform  Act of  1995.  Such  statements
relating  to  future  events  and  financial   performance  are  forward-looking
statements that involve risks and  uncertainties,  detailed from time to time in
the  Company's  various SEC  filings.  No  assurance  can be given that any such
matters will be realized.

                              RESULTS OF OPERATIONS

The Three  Months  Ended  October 31, 2004  Compared to the Three  Months  Ended
October 31, 2003

General and administrative  expenses totaled $427,057 for the three months ended
October 31, 2004 as compared to $318,787 for the three months ended  October 31,
2003,  a net  increase of  $108,270.  The net  increase is  primarily  due to an
increase in specialized consulting and legal fees as well as .

Liquidity and Capital Resources

     The Company's  primary  needs for  liquidity and capital  resources are the
funding of salaries and other administrative  expenses related to the management
of the Company.

     The Company's  cash of $48,423 as of October 31, 2004 is not  sufficient to
support  current  levels of operations for the next twelve months and it will be
necessary for the Company to seek additional financing. The Company,  therefore,
has recently sought investors and lenders and on December 22, 2004, entered into
a Subscription  Agreement with an accredited investor,  NITE Capital,  L.P. (the
"Investor"),  pursuant to which the Investor  purchased  an aggregate  principal
amount of $250,000 in an 8%  promissory  note,  and 60,096  shares of our common
stock.

     The  promissory  note bears simple  interest at 8% per annum payable on the
maturity  date,  which is the  earlier  of (i)  June  22,  2005 or (ii) the date
subsequent  to the  date of the  note  which we  enter  into  any  financing  or
financings of any type aggregating $1,500,000 or more (see Note 7).

The Company is also in discussions  with other financing  sources and intends to
obtain funds  through  credit  lines,  loans  and/or sales of its common  stock.
Should the  company  be unable to obtain  sufficient  financing,  It may have to
curtail operations.

Critical Accounting Policies

     The  Company's  discussion  and  analysis of its  financial  condition  and
results of operations are based upon In Vivo's financial statements,  which have
been prepared in accordance with accounting principles generally accepted in the
United States. The preparation of these financial statements requires the use of
estimates that affect the reported amounts of assets,  liabilities and expenses.
The Company evaluates its estimates on an ongoing basis, including estimates for
Income  tax  assets  and   liabilities  and  the  impairment  of  the  value  of
investments.  The Company bases its estimates on  historical  experience  and on
actual  information and assumptions that are believed to be reasonable under the
circumstances at that time. Actual results may differ from these estimates under
different  assumptions  or conditions.  The Company  believes that the following
critical accounting  policies affect its more significant  estimates used in the
preparation of its financial statements.

                                       -8-
<PAGE>


     Accounting for Income Taxes.

     The  Company  currently  records a full  valuation  allowance  against  the
deferred tax benefit for net operating losses  generated,  since in management's
opinion the net  operating  losses do not meet the more likely than not criteria
for future realization.


     Impairment of Investments.

     In Vivo Medical  Diagnostics,  Inc.  reviews  estimates of the value of its
investments  each reporting  period and records an impairment loss to the extent
that  management  believes  that there has been an  impairment  to the  carrying
value.

                                       -9-
<PAGE>


     Recent Accounting Pronouncements


     In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement 133 on
Derivative  Instruments  and  Hedging  Activities."  The  Statement  amends  and
clarifies  accounting for derivative  instruments,  including certain derivative
instruments  embedded in other contracts entered into or modified after June 31,
2003.  The guidance  should be applied  prospectively.  The  provisions  of this
Statement that relate to SFAS 133 Implementation Issues that have been effective
for fiscal  quarters  that began prior to June 15, 2003,  should  continue to be
applied in accordance with  respective  effective  dates.  In addition,  certain
provisions  relating to forward purchases or sales of when-issued  securities or
other securities that do not yet exist,  should be applied to existing contracts
as well as new contracts  entered into after June 31, 2003. The adoption of SFAS
No. 149 is not expected to have an impact on the Company's financial statements.

     In May 2003,  the FASB issued  Statement of  Accounting  Standards  No. 150
"Accounting  for Certain  Financial  Instruments  with  Characteristics  of both
Liabilities and Equity" (SFAS No. 150).  SFAS No. 150 establishes  standards for
classification and measurement in the statement of financial position of certain
financial  instruments with  characteristics  of both liabilities and equity. It
requires  classification of a financial instrument that is within its scope as a
liability  (or an asset in some  circumstances).  SFAS No. 150 is effective  for
financial instruments entered into or modified after May 31, 2003, and otherwise
is effective at the beginning of the first interim period  beginning  after June
15, 2003. The Company has not yet determined the impact, if any, of the adoption
of SFAS on its financial position or results of operations.


In May 2003,  the  consensus on EITF Issue No.  01-08,  "Determining  Whether an
Arrangement Contains a Lease," was issued. The guidance in the consensus applies
to the purchase or sale of goods and services  under various types of contracts,
including outsourcing arrangements. Based on the criteria in the consensus, both
parties to an  arrangement  are  required to determine  whether the  arrangement
includes a lease within the scope of SFAS No. 13,  "Accounting  for Leases." The
new  requirement  applies  prospectively  to new or  modified  arrangements  for
reporting  periods  beginning after May 28, 2003.  Accordingly,  as of August 1,
2003,  the  company  accounted  for new or modified  arrangements  based on this
guidance.  Adoption  of this  standard  did not have an impact on our  company's
financial statements.



 In December 2003,  the Financial  Accounting  Standards  Board (" FASB") issued
Interpretation  No. 46 ("FIN 46"),  "Consolidation of Variable Interest Entities
which was originally issued in January 2003. FIN 46 or revised provides guidance
on the  consolidation  of certain  entities  when control  exists  through other
entities  created after  January 31, 2003.  The Company does not hold a variable
interest  in any  enterprise.  Accordingly,  the  Company  does not  expect  the
provisions  of FIN 46 to have a  material  effect  on future  interim  or annual
financial statements.


On December 18, 2003 the SEC issued Staff  Accounting  Bulletin No. 104, Revenue
Recognition  ("SAB 104"),  which  supersedes  SAB 101,  Revenue  Recognition  in
Financial  Statements.  SAB  104's  primary  purpose  is to  rescind  accounting
guidance contained in SAB 101 related to multiple element revenue  arrangements,
which was  superseded as a result of the issuance of EITF 00-21,  Accounting for
Revenue Arrangements with Multiple Deliverables. The adoption of SAB 104 did not
have  a  material  impact  the  Company's   financial  position  or  results  of
operations.

                                           -10-
<PAGE>


ITEM 3. CONTROLS AND PROCEDURES

     Evaluation of disclosure controls and procedures.

     Our  chief  executive  officer  and  our  chief  financial  officer,  after
evaluating  our  "disclosure   controls  and  procedures"  (as  defined  in  the
Securities  Exchange  Act of 1934  (the  "Exchange  Act")  Rules  13a-14(c)  and
15d-14(c)  have concluded that as of a date within 90 days of the filing date of
this report (the "Evaluation  Date") our disclosure  controls and procedures are
effective to ensure that information we are required to disclose in reports that
we file or submit under the Exchange Act is recorded, processed,  summarized and
reported within the time periods specified in Securities and Exchange Commission
rules and forms.

     Changes in internal controls

     Subsequent to the Evaluation Date, there were no significant changes in our
internal  controls  or in other  factors  that  could  significantly  affect our
disclosure controls and procedures,  nor were there any significant deficiencies
or material  weaknesses  in our internal  controls.  As a result,  no corrective
actions were required or undertaken.

                                       11
<PAGE>


PART II   OTHER INFORMATION


ITEM 1. LEGAL PROCEEDINGS

          None

ITEM 2. CHANGES IN SECURITIES

          Mergers and issuances from 8-K


ITEM 3. DEFAULTS UPON SENIOR SECURITIES

          None


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS

          None


ITEM 5. OTHER INFORMATION

          None


ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

          EXHIBITS

     31.1  Certification of the Chief Executive  Officer pursuant to Section 312
           of the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley").

     31.2  Certification of the Chief Financial  Officer pursuant to Section 312
           of the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley").


     32.1  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
           to Section 906 of the Sarbanes-Oxley Act of 2002.


     32.2  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
           to Section 906 of the Sarbanes-Oxley Act of 2002.


     REPORTS ON FORM 8-K

          The  Company  filed a Current  Report on Form 8-K on August  10,  2004
     regarding the Change in control of the Company  pursuant to the transaction
     with Hall Effect Medical Diagnostics, Inc. which closed on July 30, 2004

          The Company  filed a Current  Report on Form 8-K on September 27, 2004
     regarding the name change from Sports  Information and Publishing  Corp. to
     In Vivo Medical  Diagnostics,  Inc. and the change in the trading symbol to
     IVVO both of which Were effective on that date

          The Company  filed a Current  Report on Form 8-K on December  29, 2004
     regarding the $250,000 loan  transaction  with NITE Capital on December 22,
     2004

                                     - 12 -

<PAGE>

ITEM 7 - SIGNATURES


                                   SIGNATURES


Pursuant to the  requirements  of the  Securities  and Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                 IN VIVO MEDICAL DIAGNOSTICS, INC.


                                 February 3, 2005


                                 By:   /s/ John Fuller
                                       -------------------
                                       John Fuller
                                       Chief Executive Officer




                                 By:   /s/ Bernard Turner
                                       -------------------
                                       Bernard Turner
                                       Chief Financial Officer

                                       - 13 -